SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : MDA - Market Direction Analysis -- Ignore unavailable to you. Want to Upgrade?

To: pater tenebrarum who wrote (48913)5/2/2000 10:13:00 AM
From: Casaubon  Read Replies (1) | Respond to of 99985
 
A lot of good biotech companies did onvertible offering to take advantage of the price run-up in stocks. By doing so, they locked in very cheap financing terms, with the potential to buy back the debt later with stock, if and/or when the companies have success in the clinic. Of course some will run out of money! If their technology is promising, they will be acquired. If it is not promising, they don't deserve more financing. There are many GREAT ideas being investigated in the biotech/drug sectors. Of course, one does not like to overpay when they buy something new so, try to be careful about entry points.



To: pater tenebrarum who wrote (48913)5/2/2000 10:28:00 AM
From: SBerglowe  Read Replies (1) | Respond to of 99985
 
Two things;
1. The anomaly in the way CHRT traded makes me think that one can track an expiring lockup and if there is a short squeeze, wait until after it has abated...and short.

2. I just noticed that TANA on LW thread is turning bullish and is pointing out that there may be a classical H& S bottoming pattern on indices. We should know, soon.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News